RU2002121771A - Композиции и способы для терапии и диагностики рака предстательной железы - Google Patents
Композиции и способы для терапии и диагностики рака предстательной железыInfo
- Publication number
- RU2002121771A RU2002121771A RU2002121771/13A RU2002121771A RU2002121771A RU 2002121771 A RU2002121771 A RU 2002121771A RU 2002121771/13 A RU2002121771/13 A RU 2002121771/13A RU 2002121771 A RU2002121771 A RU 2002121771A RU 2002121771 A RU2002121771 A RU 2002121771A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- sequences
- seq
- sequence
- polypeptide
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title claims 4
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000006853 reporter group Chemical group 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48367200A | 2000-01-14 | 2000-01-14 | |
| US09/483,672 | 2000-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002121771A true RU2002121771A (ru) | 2004-03-10 |
Family
ID=23921037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002121771/13A RU2002121771A (ru) | 2000-01-14 | 2001-01-16 | Композиции и способы для терапии и диагностики рака предстательной железы |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1261708A2 (ko) |
| JP (1) | JP2003528591A (ko) |
| KR (1) | KR20030016217A (ko) |
| CN (1) | CN1436234A (ko) |
| AU (1) | AU3447401A (ko) |
| BR (1) | BR0107643A (ko) |
| CA (1) | CA2397741A1 (ko) |
| CZ (1) | CZ20022756A3 (ko) |
| HU (1) | HUP0203968A3 (ko) |
| IL (1) | IL150732A0 (ko) |
| MX (1) | MXPA02006934A (ko) |
| NO (1) | NO20023402L (ko) |
| PL (1) | PL356908A1 (ko) |
| RU (1) | RU2002121771A (ko) |
| WO (1) | WO2001051633A2 (ko) |
| ZA (1) | ZA200206400B (ko) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US20030125536A1 (en) * | 1996-01-11 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6800746B2 (en) | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6894146B1 (en) | 1997-02-25 | 2005-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US6613872B1 (en) | 1997-02-25 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US6329505B1 (en) | 1997-02-25 | 2001-12-11 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20030185830A1 (en) * | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7202342B1 (en) | 1999-11-12 | 2007-04-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6620922B1 (en) | 1997-02-25 | 2003-09-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6759515B1 (en) | 1997-02-25 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6630305B1 (en) | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
| US6943236B2 (en) | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6818751B1 (en) | 1997-08-01 | 2004-11-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| WO1998045420A1 (en) | 1997-04-10 | 1998-10-15 | Diagnocure Inc. | Pca3, pca3 genes, and methods of use |
| US6861215B1 (en) | 1998-05-21 | 2005-03-01 | Diadexus, Inc. | Method of diagnosing, monitoring, and staging prostate cancer |
| JP4855577B2 (ja) | 1998-06-01 | 2012-01-18 | アジェンシス，インコーポレイテッド | ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用 |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
| US6902892B1 (en) | 1998-10-19 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| US7022497B1 (en) | 1999-03-11 | 2006-04-04 | Mt. Sinai Hospital | Human kallikrein-like genes |
| US6943235B1 (en) | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
| ES2260059T3 (es) | 1999-09-29 | 2006-11-01 | Diagnocure Inc. | Rna mensajero del pca3 en tejidos benignos y malignos de prostata. |
| US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| US6790631B1 (en) | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| DE60033583T2 (de) * | 1999-10-07 | 2007-09-13 | Corixa Corp. CSC, Wilmington | Eine mycobacterium tuberculosis kodierende sequenz zur expression von heterologen proteinen |
| US20020048777A1 (en) | 1999-12-06 | 2002-04-25 | Shujath Ali | Method of diagnosing monitoring, staging, imaging and treating prostate cancer |
| AU2001249549A1 (en) * | 2000-03-27 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| DK2133100T3 (da) | 2000-06-20 | 2012-01-23 | Corixa Corp | MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf |
| US20020142284A1 (en) * | 2000-07-13 | 2002-10-03 | Debasish Raha | Methods of identifying renal protective factors |
| CA2417671A1 (en) * | 2000-07-28 | 2002-02-07 | Ulrich Wissenbach | Trp8, trp9 and trp10, novel markers for cancer |
| US7048931B1 (en) | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| EP2280030A3 (en) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| JP2005504513A (ja) * | 2001-05-09 | 2005-02-17 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
| US6897024B2 (en) | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
| CA2633171C (en) | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
| US20050272120A1 (en) | 2001-06-20 | 2005-12-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| EP2287186B1 (en) * | 2001-09-06 | 2014-12-31 | Agensys, Inc. | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| US7371841B2 (en) | 2002-01-25 | 2008-05-13 | Regents Of The University Of California | Methods of modulating cold sensory perception |
| DE10215321A1 (de) * | 2002-04-02 | 2003-10-23 | Metagen Pharmaceuticals Gmbh | Trp-p8 Splice Varianten und regulatorische RNA |
| CN100360558C (zh) * | 2002-06-11 | 2008-01-09 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| DE10234901A1 (de) * | 2002-07-26 | 2004-02-12 | Metagen Pharmaceuticals Gmbh | Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| US20050282170A1 (en) | 2003-02-07 | 2005-12-22 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
| BRPI0418766B8 (pt) | 2004-04-22 | 2021-05-25 | Agensys Inc | anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico |
| CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
| EP1916298B1 (en) * | 2005-06-14 | 2011-12-28 | Dnavec Corporation | Methods for producing monoclonal antibodies |
| EP2061814B1 (en) | 2006-10-27 | 2012-06-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| MA37681B2 (fr) * | 2012-05-25 | 2020-07-29 | Cellectis | Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie |
| CN104357451B (zh) * | 2014-12-02 | 2016-09-21 | 广州市番禺区中心医院 | 针对dd3基因的小干扰rna及其表达载体构建与应用 |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201520566D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| CN116970060A (zh) * | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| CN110494452B (zh) | 2017-04-03 | 2023-08-25 | 豪夫迈·罗氏有限公司 | 结合steap-1的抗体 |
| CN110988348B (zh) * | 2019-11-06 | 2022-07-05 | 北京九强生物技术股份有限公司 | 游离前列腺特异性抗原检测试剂盒及其制备方法 |
| CN114250238B (zh) * | 2021-11-26 | 2023-08-25 | 北京航空航天大学 | 基因编码的神经元发育调控多肽及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997033909A2 (en) * | 1996-03-15 | 1997-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
| TR199902053T2 (xx) * | 1997-02-25 | 2000-04-21 | Corixa Corporation | Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar. |
| ATE302414T1 (de) * | 1997-02-25 | 2005-09-15 | Corixa Corp | Verbindungen zur immundiagnose von prostatakrebs und deren verwendung |
| KR20070112860A (ko) * | 1998-07-14 | 2007-11-27 | 코릭사 코포레이션 | 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법 |
| AU7994200A (en) * | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| JP2004537252A (ja) * | 1999-11-12 | 2004-12-16 | コリクサ コーポレイション | 前立腺癌の治療及び診断のための組成物及び方法 |
-
2001
- 2001-01-16 HU HU0203968A patent/HUP0203968A3/hu unknown
- 2001-01-16 KR KR1020027009144A patent/KR20030016217A/ko not_active Application Discontinuation
- 2001-01-16 CZ CZ20022756A patent/CZ20022756A3/cs unknown
- 2001-01-16 BR BR0107643-4A patent/BR0107643A/pt not_active Application Discontinuation
- 2001-01-16 MX MXPA02006934A patent/MXPA02006934A/es unknown
- 2001-01-16 CN CN01806526A patent/CN1436234A/zh active Pending
- 2001-01-16 AU AU34474/01A patent/AU3447401A/en not_active Abandoned
- 2001-01-16 IL IL15073201A patent/IL150732A0/xx unknown
- 2001-01-16 CA CA002397741A patent/CA2397741A1/en not_active Abandoned
- 2001-01-16 PL PL01356908A patent/PL356908A1/xx unknown
- 2001-01-16 EP EP01906582A patent/EP1261708A2/en not_active Withdrawn
- 2001-01-16 RU RU2002121771/13A patent/RU2002121771A/ru unknown
- 2001-01-16 WO PCT/US2001/001574 patent/WO2001051633A2/en not_active Application Discontinuation
- 2001-01-16 JP JP2001551207A patent/JP2003528591A/ja active Pending
-
2002
- 2002-07-15 NO NO20023402A patent/NO20023402L/no not_active Application Discontinuation
- 2002-08-12 ZA ZA200206400A patent/ZA200206400B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0107643A (pt) | 2003-06-10 |
| PL356908A1 (en) | 2004-07-12 |
| KR20030016217A (ko) | 2003-02-26 |
| NO20023402L (no) | 2002-08-29 |
| HUP0203968A3 (en) | 2004-09-28 |
| AU3447401A (en) | 2001-07-24 |
| HUP0203968A2 (hu) | 2003-03-28 |
| CZ20022756A3 (cs) | 2003-02-12 |
| JP2003528591A (ja) | 2003-09-30 |
| WO2001051633A2 (en) | 2001-07-19 |
| CA2397741A1 (en) | 2001-07-19 |
| CN1436234A (zh) | 2003-08-13 |
| WO2001051633A9 (en) | 2002-10-31 |
| IL150732A0 (en) | 2003-02-12 |
| ZA200206400B (en) | 2004-01-21 |
| EP1261708A2 (en) | 2002-12-04 |
| NO20023402D0 (no) | 2002-07-15 |
| WO2001051633A3 (en) | 2002-06-20 |
| MXPA02006934A (es) | 2003-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002121771A (ru) | Композиции и способы для терапии и диагностики рака предстательной железы | |
| JP6268129B2 (ja) | 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 | |
| Walter et al. | Antibodies specific for the carboxy-and amino-terminal regions of simian virus 40 large tumor antigen. | |
| JP2005504513A5 (ko) | ||
| CA2468258A1 (en) | Peptide agonists of prostate-specific antigen, and uses therefor | |
| JP2006515749A5 (ko) | ||
| Wakabayashi et al. | Immunospecificity of nonhistone proteins in chromatin | |
| RU2002130715A (ru) | Композиции и способы терапии и диагностики рака молочной железы | |
| JP2004512824A5 (ko) | ||
| KR20150132479A (ko) | 복합 유전자 세트에서의 독특하게 태그되고 재배열된 적응 면역 수용체 유전자 | |
| KR20140039318A (ko) | 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자 | |
| CA2414331A1 (en) | Pd-l2 molecules: novel pd-1 ligands and uses therefor | |
| CA2269634A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
| WO2018148378A1 (en) | Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy | |
| US20090324596A1 (en) | Methods of identifying and treating poor-prognosis cancers | |
| WO2003037267B1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| WO2019014663A1 (en) | MODULATION OF BIOMARKERS TO INCREASE ANTI-TUMOR IMMUNITY AND IMPROVE THE EFFECTIVENESS OF CANCER IMMUNOTHERAPY | |
| Gorski et al. | Serological and immunochemical analysis of the products of a single HLA DR-alpha and DR-beta chain gene expressed in a mouse cell line after DNA-mediated cotransformation reveals that the beta chain carries a known supertypic specificity. | |
| Zähringer et al. | Mechanism of iron induction of ferritin synthesis | |
| CA2325605A1 (en) | Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein said peptides bind to mhc class i and mhc class ii molecules, and uses thereof | |
| WO1997011968A2 (en) | A gene associated with liver neoplastic disease | |
| CA2287571A1 (en) | Reagents and methods useful for detecting diseases of the prostate | |
| RU2002128922A (ru) | Композиции и способы для лечения и диагностики рака легких | |
| Pyles et al. | Novel protein isoforms of the APC tumor suppressor in neural tissue | |
| CN113980143B (zh) | 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用 |